Objective: To evaluate the effect of using wearable activity monitors (WAMs) in patients with intermittent claudication (IC) within a single-center randomized controlled trial. Background: WAMs allow users to set daily activity targets and monitor their progress. They may offer an alternative treatment to supervised exercise programs (SEPs) for patients with IC. Methods: Thirty-seven patients with IC were recruited and randomized into intervention or control group. The intervention consisted of a feedbackenabled, wrist-worn activity monitor (WAM) in addition to access to SEP. The control group was given access to SEP only. The outcome measures were maximum walking distance (MWD), claudication distance (CD), and quality of life as measured by the VascuQol questionnaire. Participants were assessed upon recruitment, and at 3, 6, and 12 months. Results: Patients in the WAM group showed significant improvement in MWD at 3 and 6 months (80-112 m, to 178 m; P < 0.001), which was sustained at 12 months. The WAM group also increased CD (40 vs 110 m; P < 0.001) and VascuQol score (4.7 vs 5.8; P ¼ 0.004). The control group saw a temporary increase in VascuQol score at 6 months (4.5 vs 4.7; P ¼ 0.028), but no other improvements in MWD or CD were observed. Significantly higher improvements in MWD were seen in the WAM group compared with that in the control group at 6 months (82 vs À5 m; P ¼ 0.009, r ¼ 0.47) and 12 months (69 vs 7.5 m; P ¼ 0.011, r ¼ 0.52). Conclusions: The study demonstrates the significant, sustained benefit of WAM-led technologies for patients with IC. This potentially resource-sparing intervention is likely to provide a valuable adjunct or alternative to SEP.
P eripheral arterial disease commonly manifests as intermittent claudication (IC), which is characterized by pain in the legs when walking. IC is a highly prevalent and debilitating condition that affects 6% of patients older than 60 years of age. 1 It results in significant walking impairment and subsequently a poor quality of life.
1,2
The mainstay of treatment for patients suffering from IC is the provision of supervised exercise programs (SEPs) and the management of cardiovascular risk factors. 3 Although SEPs have been shown to improve walking distances and quality of life in clinical studies, 4 in practice, there are a number of important barriers to its implementation. In particular, patient compliance is poor and may be as low as 34%. 5 Additionally, if exercise levels are not maintained after completion of the program, the gained benefits in walking distance are quickly lost. 6 This risk is significant as exercise classes cannot be easily recreated by the patient or incorporated into one's daily routine. This is particularly important in a group of patients who have been shown to have a reduced level of overall physical activity as compared with the rest of population. 7 Furthermore, SEPs are expensive, and survey studies suggest that only one-third of vascular surgeons have access to a SEP for their patients. 8, 9 Clearly, a system must be developed which minimizes the use of healthcare resources while maximizing patient motivation and results in sustainable solutions to patient engagement. Commercially available wearable activity trackers may have a role to play in engaging patients and promoting physical activity.
The primary aim of this study was to determine whether the use of a feedback-enabled wearable activity monitor (WAM) improves walking distances and quality of life in patients with IC.
METHODS

Study Protocol
We conducted a single-center, pilot, randomized controlled trial at a regional tertiary referral center. The study was approved by the National Research Ethics Committee (reference no. 12/LO/1896). The study is listed in the ClinicalTrials.gov registry (identifier no. NCT01822457). All recruited participants provided written informed consent. Consecutive patients with claudication were identified at outpatient clinics by members of the clinical teams over a 14-month period (October 2013 to December 2014) and were invited to participate in the study. All patients followed a standardized clinical pathway including routine clinical assessment and Duplex ultrasound imaging. Patients were also seen in a Vascular Nurse Specialist-led claudication clinic, as per our institution regimen. Here, cardiovascular risk factors were further assessed and optimized, routine information on maintaining physical activity was provided, and patients were advised to attend a SEP. The SEP consists of a 1-hour exercise class per week for 3 months, under the supervision of a 'Physiotherapist' and 'Vascular Nurse Specialist.'
Inclusion and Exclusion Criteria
Patients with intermittent calf claudication between the ages of 40 and 90 were recruited. Claudication was determined by documented current symptoms and evidence of hemodynamically significant superficial femoral artery (SFA) stenosis on Duplex ultrasonography.
Patients were excluded in the presence of the following: other conditions limiting mobility more than their claudication (such as severe arthritis or breathlessness), walking aid use, a reported walking distance of >500 m, and a revascularization procedure in the past 6 months.
Patients who were eligible and had expressed interest to participate were then invited to attend a clinic appointment with a member of the research team. Here, the study was discussed in full, eligibility for inclusion assessed, and informed consent obtained. Patients were asked to complete a questionnaire to collect baseline demographics. Baseline quality of life and walking distance outcome measures were then collected before randomization. Each patient was randomly allocated to either a WAM group or a control group in a 1:1 ratio using a computerized block randomization technique with randomly selected block sizes. Each allocation was placed in an opaque envelope with a unique study number at the front by an independent observer who was not involved in further aspects of the study. 10 
Intervention
The Nikeþ FuelBand (Nike, Inc., OR) (Fig. 1A) is a commercially available wrist-worn activity monitor with a built-in accelerometer, which allows for motion quantification. It also allows for personalized goal setting and displays real-time feedback regarding progression towards goals. Users are able to monitor activity levels using a number of metrics, which include number of steps, calorie expenditure, and 'fuel-points' (a metric of overall 'movement' and activity), all available on a LED display on the band. The device also offers a number of interactive behavior change tools via the graphical interface of the band with a paired mobile device or computer. These include reminders to keep active, interactive graphs of activity, activity statistics, and comparison of activity with one's peers or a broader community of users (Fig. 1B) .
At the initial clinical visit, patients randomized to the WAM group were given an introduction to the functionality of the Nike Fuelband and then asked to demonstrate that they could operate its basic functions (by author P.N.). Personalized accounts were created on the NikePlus website to allow trends in activity to be reviewed at 3, 6, and 12-month follow-up visits. Daily activity targets were programmed into the band by the research team and patients were asked to wear their bands every day for 1 year. Initial daily targets were set at 2000 fuel points as this was suggested as a 'normal' daily target by Nike and was felt achievable from our research teams initial trial experiences with the band. Progress with daily goals was reviewed at each follow-up visit with patients. If the daily goal was achieved on 75% of days, it was increased by 10% to 20%, depending on what the patient felt achievable after reviewing their activity trends. Targets were kept the same for those patients who achieved their daily targets on 50% to 75% of days and decreased by 10% to 20% for those who achieved their daily goal less than 50% of days.
Any technical issues experienced by the patient were addressed at the subsequent follow-up appointment. However, if more timely technical support was required, that is, band replacements, patients were asked to collect a replacement band or it was posted to their home address.
Outcome Measures
Primary outcome measure was treadmill measured maximum walking distance (MWD). Secondary outcome measures were treadmill measured claudication distance (CD) and quality of life as measured by the Vascular Quality of Life Questionnaire (VascuQol). The VascuQol tool is a 25-item questionnaire with 7-point response options (1 ¼ worse possible score and 7 ¼ best possible score). The questions are divided into 5 categories: pain, symptoms, activities, emotional, and social. An average is taken for all items to give equal weight to each question and domain (minimum score of 1 and maximum score of 7). Upon enrolment, each patient underwent MWD, CD, and VascuQol assessments, which were repeated at 3, 6, and 12 months.
Walking distances were assessed using a constant-load treadmill test (2.5 km/h) with a 108 incline for a maximum of 500 m. Patients were rested for 20 minutes before the treadmill test, and once on the treadmill, they were not allowed to hold the handrails. Initial CD (the distance at which symptoms of ischemic lower-limb muscle pain began) and MWD (the distance at which the patient could not walk any further) were recorded. All patients completed the VascuQoL questionnaire, which is a validated, disease-specific quality-oflife assessment tool. 11 
Statistical Analysis
As this was a pilot study assessing feasibility, formal power calculations were not performed. Descriptive statistics were obtained and tested for normal distribution using the Kolmogorov-Smirnov test. The walking distance data and the quality of life data were normally distributed, so nonparametric tests were used. The Wilcoxon signed-rank test was used to analyze differences with longitudinal group data. Differences between groups were analyzed using the Mann-Whitney U test. Effect size (r) was calculated for each outcome of interest and interpreted using previously suggested descriptive terms; an effect size of 0.1 is 'small,' a value of 0.3 is 'medium,' and a value of 0.5 is 'large.' 12 Correlation between quality-of-life score and walking distances were calculated using the Spearman rank-correlation coefficient (r s ). Data were analyzed using IBM SPSS Statistics version 23 (IBM, Armonk, New York, NY).
RESULTS
Eighty-nine patients were referred for assessment. After referral, 52 patients were excluded as they were not eligible (n ¼ 20), could not be contacted (n ¼ 11), or declined to participate owing to travel distance or time constraints (n ¼ 21). Thirty-seven patients were randomized (20 WAMs, 17 controls). Patient demographics were well-balanced between the 2 groups (Table 1) .
In the WAM group, 4 patients withdrew from the study: 1 patient had worsening chronic obstructive pulmonary disease and heart failure, 2 withdrew due to family bereavement, and 1 patient had worsening claudication symptoms and underwent an angioplasty.
In the control group, 5 patients withdrew from the study: 3 patients withdrew due to health-related issues (stroke, lung cancer, and septic arthritis), 1 patient underwent surgery for worsening symptoms and critical limb ischemia, and 1 patient was lost to follow-up.
Accounting for patients withdrawn from the study and those not able to attend their follow-up appointments, data were analyzed for 37 patients at baseline, 28 at 3 months (19 WAMs, 9 controls), 31 at 6 months (18 WAMs, 13 controls), and 24 at 12 months (16 WAMs, 8 controls) (Fig. 2) .
Intragroup Analysis
Considering our primary outcome measure MWD, patients in the WAM group made a statistically significant improvement in median MWD at 3 months (80 vs 112 m; P ¼ 0.013). By 6 months, this group had more than doubled their MWD as compared with baseline (80 vs 178 m; P < 0.001) and also made a significant improvement as compared with 3 months (112 vs 178 m; P ¼ 0.006). At 12 months, the MWD had plateaued with no significant difference in 6-month results (178 vs 147 m; P ¼ 0.3). Patients in the control group made no significant improvement in MWD over the course of the study when compared with baseline (68 m), 3 months (80 m; P ¼ 0.11), 6 months (83 m; P ¼ 0.36), and 12 months (68 m; P ¼ 0.33) (Fig. 3) . 
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Considering CD, patients in the WAM group made a statistically significant improvement in median CD at 3 months (40 vs 54 m; P ¼ 0.017). By 6 months, this group had almost trebled their CD as compared with baseline (40 vs 115 m; P < 0.001) and also significantly improved compared with 3 months (54 vs 115 m; P ¼ 0.005).
As with MWD, this improvement was also maintained at 12 months follow-up (115 vs 110 m; P ¼ 0.35) and was still significantly higher than baseline (P ¼ 0.001). Patients in the control group made no significant improvement in CD over the course of the study when compared with baseline (36 m), 3 months (28 m; P ¼ 0.26), 6 months (45 m; P ¼ 0.18), and 12 months (43.5 m; P ¼ 0.13) (Fig. 4) .
Patients in the WAM group made a statistically significant improvement in quality of life, as measured by VascuQol scores, over the course of the study compared with baseline (4.7), 3 months (5.4; P < 0.001), 6 months (5.6; P ¼ 0.001), and 12 months (5.8; P ¼ 0.004). There were no significant differences in VascuQol scores between 3 and 6 months (5.4 vs 5.6; P ¼ 0.08) or 6 and 12 months (5.6 vs 5.8; 0.26). Patients in the control group had no significant change in quality-of-life scores at 3 months (4.5 vs 3.5; P ¼ 0.64), but had a small but statistically significant increase at 6 months compared with baseline (4.5 vs 4.7; P ¼ 0.028). Their scores then decreased again at 12 months, with levels not statistically different to baseline (4.5 vs 3.3; P ¼ 0.58) (Fig. 5) . Table summary of intragroup analysis data is provided online (online-only supplemental data content, Table 2 , http://links.lww.com/SLA/B232).
Intergroup Analysis
On comparison of magnitude of change, there was no statistically significant difference in improvement in MWD between the WAM and control group at 3 months (15.5 vs 20 m; P ¼ 0.78, r ¼ 0.06). However, there were significantly greater improvements in the WAM group at 6 months (82 vs À5 m; P ¼ 0.009, r ¼ 0.47) and 12 months (69 vs 7.5 m; P ¼ 0.011, r ¼ 0.52) compared with the control group.
When considering CD, again no statistically significant difference was found between the 2 groups at 3 months (11.5 vs 8 m; P ¼ 0.32, r ¼ 0.2). However, there were significantly higher improvements in the WAM at 6 months (63 vs 10 m; P ¼ 0.002, r ¼ 0.54) and 12 months (38 vs 11 m; P ¼ 0.011, r ¼ 0.52) follow-up.
When considering VascuQol, scores were significantly improved in the WAM group at 3 months (0.78 vs 0.04; P ¼ 0.004, r ¼ 0.53), 6 months (0.9 vs 0.2; P ¼ 0.031, r ¼ 0.39), and FIGURE 3. Box plot of maximum walking distances for wearable activity monitor (WAM) and control group over the course of the study ( Ã P < 0.05). 
DISCUSSION
This study showed the positive effect of a feedback-enabled, wrist-worn activity monitor in patients with IC. Patients in the intervention group demonstrated significant improvements in MWD, CD, and quality of life at 3 and 6 months, which were maintained at 12 months. This was in contrast to the control group, which, despite access to SEP, failed to show improvement in any outcome measure. After 6 months with the WAM, patients on average could walk 82 m further, 63 m without pain, and had increased their VascuQol score by 0.9 (on a scale of 1-7). These improvements are clinically significant, with additional walking capacity able to transform patients' daily lives and activities, as supported by the positive correlation between improvement in walking distance and quality-of-life scores.
Wearing an activity monitor is a constant reminder to the patient and those around them of their commitment to rehabilitate, and their choice to take responsibility for their health. The personalized walking goals motivate the patient by providing tangible daily targets. These targets not only provide reference to population norms, but are also set after discussion with the patient so that they feel directly involved in their own disease management. Furthermore, the accompanying software gives the added incentive of a visible record of how often these goals were met, thereby engaging them to modify their health behaviors.
The intervention described has the benefit of incorporating exercise into the daily routine, which gives more potential for sustainability. This is unlike SEP, which not only can be difficult to access but also can seem quite separate from daily activities. When the number of allotted sessions ends, it is difficult for the patient to recreate the activities and often the positive effects are gradually lost. SEP is relatively resource-demanding, with need for exercise space and healthcare professionals to lead, and administrative staff to organize. It is also time-consuming and potentially expensive for the patient to attend classes during working hours. Despite these issues, there is good evidence to support SEP when attended well, and is the current best practice recommendation from the National Institute of Clinical Excellence (NICE).
3 NICE also recommends the investigation of WAMs as an important research question in PAD.
A new generation of WAMs became commercially available in the turn of the century, stimulated by the developed worlds' increasing health awareness and facilitated by developments in technology. Pedometers have a proven effect in healthy adults; a meta-analysis has demonstrated that their use increases daily activity by 2491 steps. 13 Whereas this meta-analysis was devoid of PAD patients, there has been a call for pedometer or accelerometer use as a semistructured alternative for home-based exercise programs. 5 Activity monitoring by these devices has been validated in PAD and has been shown to be a useful adjunct for activity measurement. 5, 14, 15 Tri-axial accelerometers in particular are considered significantly more accurate for daily activity assessment compared with pedometers. 16 Two studies have investigated the use of activity monitors on walking in IC. Gardner et al 17 investigated the effects of a step watch alongside SEP, which showed improvements in walking distance; yet patient follow-up was limited to 3 months and therefore the sustainability is unknown. Nicolaï et al 18 used a personal activity monitor over 1 year, which failed to show improvements beyond those of a SEP. However, the particular sensor chosen required the patient to manually download and document data each day, unlike more modern sensors, which allow real-time feedback. This improvement in usability is likely to yield a stronger psychological intervention. Our study builds on the current evidence by demonstrating both the clinical impact and longevity of such an intervention over 1 year. Although benefits gained during the first 6 months were maintained at 1 year, we did note a plateau in performance in the latter half of the study. Less engagement with the WAM may be a possible reason for this observation, but further work is needed to explore this in detail.
Although formal cost-effectiveness analysis is beyond the scope of this study, wearable activity trackers are likely to provide a resource sparing solution to IC management. WAMs are available for as little as £30. In contrast, a 3-month supervised exercise program is estimated to cost between £232 and £345 per patient. 19 WAMs may potentially be used in a number of different formats, for example, as an adjunct to hospital or community-based exercise programs. Alternatively, they may be used in combination with an online-coaching platform to promote physical activity and optimize cardiovascular risk factors.
Feedback from patients in the WAM group of our study has been extremely positive and many have continued to use the devise after completion of the study. Selected comments from patients, such as ''it motivates me to get out of the house'' and ''the band challenges me to walk more every day,'' highlight the empowering and motivating effects of this technology.
Limitations
The findings of this study must be interpreted in the context of study limitations. During recruitment, whereas all eligible patients were approached, approximately half declined to participate or were not eligible for the study. It is possible that participants successfully recruited are more inclined to use technology compared with the general population. However, it is also worth noting that the use of technological devices, such as WAMs, in older patients, is feasible.
A randomized controlled trial design was used to minimize selection bias; however, due to resource restraints, the investigators were not blinded to allocation during walking assessments. Whereas strict protocol was adhered to with regards to patient-investigator interactions, it may have resulted in WAM patients putting in more effort and performing better.
As both groups had access to SEPs, it makes it difficult to distinguish the effect from the WAM to that of the exercise class. Weekly attendance to the SEPs was not recorded during the study, and this information was not available retrospectively through clinical records. There was, however, a record of enrollment to SEP, which was relatively low (22%, 8 patients), and so this is unlikely to have had a significant impact on our results. Furthermore, there were fewer patients in the WAM group enrolled as compared with the control group [3 (15%) vs 5 (29%); P ¼ 0.25].
Similarly, although interval feedback given to the WAM group regarding activity levels was standardized and targets were changed based on a predefined set protocol, this interaction may have had a role in enhancing the positive effects of the WAM.
Finally, participant attrition weakened the statistical analysis throughout the study. However, statistical significance was still found due to the marked effect of the WAM. Attrition was similar in both groups (n ¼ 4 and 5), and can be largely attributed to the patient demographic and comorbidities. Only 1 patient was lost to follow-up without adequate explanation.
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CONCLUSIONS
With increasing burden of peripheral vascular disease, an affordable population-based strategy with sustained impact is required. WAMs are accessible, inexpensive, and may therefore provide a scalable solution to promoting physical activity. This study strongly suggests considerable benefit in physical function and quality of life through the use of a WAM in this challenging patient group. The projected improvement to patient care with such a potentially resource-sparing intervention is worthy of further conclusive assessment of benefit and cost-effectiveness through a multicenter randomized trial. Additional considerations must be made with regards to the potential security issues of transmitting patient data using online platforms, and also the need for supporting IT infrastructure and data compatibility with electronic health records.
